BioCryst Pharmaceuticals (NASDAQ:BCRX) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $8.56 and traded as high as $9.48. BioCryst Pharmaceuticals shares last traded at $9.38, with a volume of 1,635,305 shares trading hands.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Cantor Fitzgerald increased their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. Citizens Jmp lifted their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, May 7th. Needham & Company LLC reduced their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Finally, Wedbush decreased their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eight equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

BioCryst Pharmaceuticals Price Performance

The firm has a market capitalization of $2.38 billion, a PE ratio of -5.27 and a beta of 0.55. The stock has a 50-day moving average price of $9.21 and a 200-day moving average price of $8.56.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). The business had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 EPS. As a group, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.58 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Wedge Capital Management L L P NC purchased a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at approximately $3,808,000. Assenagon Asset Management S.A. increased its stake in shares of BioCryst Pharmaceuticals by 51.6% in the second quarter. Assenagon Asset Management S.A. now owns 353,044 shares of the biotechnology company’s stock worth $3,530,000 after buying an additional 120,097 shares during the last quarter. Pacer Advisors Inc. bought a new stake in shares of BioCryst Pharmaceuticals in the first quarter worth $14,880,000. Seven Fleet Capital Management LP acquired a new stake in BioCryst Pharmaceuticals in the first quarter valued at $976,000. Finally, NewEdge Advisors LLC raised its holdings in BioCryst Pharmaceuticals by 4.6% in the first quarter. NewEdge Advisors LLC now owns 52,326 shares of the biotechnology company’s stock valued at $498,000 after acquiring an additional 2,285 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.